Monitor Neurolief's revenue trajectory for potential $5 million equity tranche trigger and assess likelihood of BrainsWay exercising its acquisition option. The FDA approval and VA access create near-term commercial upside for Neurolief, which could significantly enhance BrainsWay's long-term value if it exercises its call option.
Price Chart
Executive Summary
BrainsWay completed a $6 million milestone-based convertible loan to Neurolief following FDA approval of Neurolief's ProlivRx system for treatment-resistant major depressive disorder. This brings BrainsWay's total investment in Neurolief to $11 million, with potential for an additional $5 million equity investment and a call option to acquire Neurolief outright.
Key Facts
- BrainsWay invested an additional $6 million in Neurolief via a convertible loan, triggered by FDA PMA approval of ProlivRx for MDD.
- Total investment by BrainsWay in Neurolief now stands at $11 million.
- Potential for an additional $5 million equity investment if Neurolief hits a revenue-based target.
- BrainsWay holds a call option to acquire all of Neurolief at a price based on enterprise value or revenue multiple.
- ProlivRx is the first FDA-approved at-home neurostimulation device for treatment-resistant MDD.
- Neurolief has secured placement on the VA Federal Supply Schedule, enabling access to the U.S. veterans healthcare system.
Financial Impact
$6 million in new capital deployed; total exposure now $11 million with potential for $5 million more; possible future acquisition of Neurolief.
Risk Factors
- Execution risk in Neurolief's commercialization of ProlivRx despite FDA approval.
- Potential dilution or balance sheet impact if BrainsWay exercises future investment tranches or acquisition option.
- Regulatory or reimbursement challenges for at-home neurostimulation adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-001925 |
| Document: f6k_032526.htm | 0001171843-26-001925 |
| Document: 0001171843-26-001925-index-headers.html | 0001171843-26-001925 |
| Document: 0001171843-26-001925-index.html | 0001171843-26-001925 |
| Document: 0001171843-26-001925.txt | 0001171843-26-001925 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 6-K | $14.16 $13.63 | ▼ −3.74% | ▼ −3.08% | $12.71 (−10.24%) |
Aug 27, 2026 5w ago | 6-K | $14.40 $14.51 | ▲ +0.76% | ▲ +0.50% | $12.71 (−11.74%) |
Aug 12, 2026 7w ago | 6-K | $16.47 $14.97 | ▼ −9.11% | ▼ −7.14% | $12.71 (−22.83%) |
Aug 12, 2026 7w ago | 6-K | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Aug 12, 2026 7w ago | Press Release | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Jul 20, 2026 10w ago | 6-K | $16.50 $15.97 | ▼ −3.21% | ▼ −2.79% | $12.71 (−22.97%) |
Jul 16, 2026 11w ago | 6-K | $14.84 $16.51 | ▲ +11.25% | ▲ +12.92% | $12.71 (−14.35%) |
Jun 29, 2026 13w ago | Press Release | $15.17 $16.02 | ▲ +5.60% | ▲ +4.22% | $12.71 (−16.22%) |
Jun 22, 2026 14w ago | 6-K | $14.38 $15.17 | ▲ +5.49% | ▲ +5.95% | $12.71 (−11.61%) |
May 18, 2026 19w ago | Press Release | $14.88 $15.89 | ▲ +6.79% | ▲ +5.17% | $12.71 (−14.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access